James F. Oliviero III, C.F.A., CFA
Net Worth

Last updated:

What is James F. Oliviero III, C.F.A., CFA net worth?

The estimated net worth of Mr. James F. Oliviero III, C.F.A., CFA is at least $21,160,287 as of 19 Dec 2024. He owns shares worth $13,608,924 as insider, has earned $4,214,163 from insider trading and has received compensation worth at least $3,337,200 in Checkpoint Therapeutics, Inc..

What is the salary of James F. Oliviero III, C.F.A., CFA?

Mr. James F. Oliviero III, C.F.A., CFA salary is $834,300 per year as Chief Executive Officer, Pres & Director in Checkpoint Therapeutics, Inc..

How old is James F. Oliviero III, C.F.A., CFA?

Mr. James F. Oliviero III, C.F.A., CFA is 49 years old, born in 1976.

What stocks does James F. Oliviero III, C.F.A., CFA currently own?

As insider, Mr. James F. Oliviero III, C.F.A., CFA owns shares in one company:

Company Title Shares Price per share Total value
Checkpoint Therapeutics, Inc. (CKPT) Chief Executive Officer, Pres & Director 3,194,583 $4.26 $13,608,924

What does Checkpoint Therapeutics, Inc. do?

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

James F. Oliviero III, C.F.A., CFA insider trading

Checkpoint Therapeutics, Inc.

Mr. James F. Oliviero III, C.F.A., CFA has made 18 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 220,230 units of CKPT stock worth $744,377 on 19 Dec 2024.

The largest trade he's ever made was exercising 602,167 units of CKPT stock on 18 Dec 2024. As of 19 Dec 2024 he still owns at least 3,194,583 units of CKPT stock.

Transaction Date Security Shares Price per share Total value Source
Sale
COMMON STOCK 220,230 $3.38 $744,377
Sale
COMMON STOCK 602,167 $3.87 $2,330,386
Sale
COMMON STOCK 24,610 $2.05 $50,450
Sale
COMMON STOCK 5,894 $2.06 $12,142
Sale
COMMON STOCK 11,900 $2.01 $23,919
Sale
COMMON STOCK 5,483 $5 $27,415
Sale
COMMON STOCK 5,548 $4.65 $25,798
Sale
COMMON STOCK 10,261 $4.77 $48,945
Sale
COMMON STOCK 3,817 $6.75 $25,761
Sale
COMMON STOCK 15,000 $1.11 $16,650
Sale
COMMON STOCK 12,000 $1.09 $13,080
Sale
COMMON STOCK 21,000 $1.09 $22,890
Sale
COMMON STOCK 228,000 $1.09 $248,520
Sale
COMMON STOCK 21,258 $1.51 $32,100
Sale
COMMON STOCK 14,030 $1.77 $24,833
Sale
COMMON STOCK 86,353 $1.79 $154,572
Sale
COMMON STOCK 48,790 $3.42 $166,764
Sale
COMMON STOCK 70,000 $3.51 $245,560

Checkpoint Therapeutics key executives

Checkpoint Therapeutics, Inc. executives and other stock owners filed with the SEC: